December 10, 2024

BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY

Company will showcase new assay at the upcoming San Antonio Breast Cancer Symposium

MINNEAPOLIS, Dec. 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, launched a highly sensitive *ESR1* mutation monitoring assay. *ESR1* gene mutations are known to be linked to hormone receptor-positive (HR+) metastatic breast cancer. The research-use-only assay, which consists of a qPCR detection kit as well as an isolation kit for cell-free DNA and exosomal RNA, will be featured in the Asuragen booth (#1429) at the San Antonio Breast Cancer Symposium beginning on December 10th.

While mutations in the *ESR1* gene are exceedingly rare in cancer patients prior to treatment, the use of endocrine therapies leads to the emergence of *ESR1* mutations in as many as 40% of patients with HR+ metastatic breast cancer. Identifying these mutations as quickly as possible is crucial for clinicians to spot the early warning signs of treatment resistance and adjust course as appropriate. Unfortunately, most molecular testing technologies lack the sensitivity needed to reliably and cost-effectively detect these mutations.

Asuragen's new *ESR1* mutation assay, which consists of the QuantideX® qPCR *ESR1* exoMutation Kit paired with the ExoLution™ Plus cfDNA + exoRNA Isolation Kit, was designed to detect 11 *ESR1* ligand-binding domain mutations in samples at very high sensitivity. It can be used with widely available qPCR technology for easy implementation without the added cost of adopting a new platform. By detecting the molecular signal from both cell-free DNA and exosomal RNA, the assay achieves sensitivity levels that were previously only attainable with much more expensive, cumbersome, or lower plex technologies.

"With a growing number of candidate drugs targeting *ESR1* mutations in clinical trials, it is more important than ever for laboratory scientists to be able to spot the emergence of these mutations among individuals who have been treated with aromatase inhibitors and other endocrine therapies," said Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment. "Pairing our deep expertise in developing highly sensitive, qPCR-based assays with our capabilities in extracting data from exosomes, puts Bio-Techne in a unique position to provide a high-quality, streamlined, and multiplexed *ESR1* mutation assay for broad use in clinical research laboratories."

For more product information, please visit https://asuragen.com/portfolio/oncology/quantidex-esr1-exomutation-kit/.

Asuragen's ESR1 mutation assay is intended for research use only and is not meant for use in diagnostic procedures.

About Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com or follow the Company on social media at Facebook, LinkedIn, Twitter or YouTube.

About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-launches-esr1-mutation-monitoring-assay-302325875.html

SOURCE Bio-Techne Corporation